|
19 Dec 2011 |
Selexys Pharmaceuticals Completes Phase I Clinical Study for Sickle Cell Drug
|
|
17 Dec 2011 |
ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule
|
|
17 Dec 2011 |
AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
|
|
15 Dec 2011 |
Human Genome Sciences and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus Erythematosus
|
|
14 Dec 2011 |
Clinical development of BT-062 in multiple myeloma expands into combination therapy
|
|
14 Dec 2011 |
Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody
|
|
14 Dec 2011 |
Immunomedics Announces Results From Two Clinical Trials at Hematology Conference
|
|
14 Dec 2011 |
Profectus BioSciences, Inc. Receives $5.4M Grant to Develop a Monocolonal Antibody Against Infection by Nipah/Hendra Viruses
|
|
14 Dec 2011 |
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
|
|
14 Dec 2011 |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
|
|
14 Dec 2011 |
Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
|
|
13 Dec 2011 |
Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS™ (Brentuximab Vedotin) in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting
|
|
13 Dec 2011 |
Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH
|
|
13 Dec 2011 |
Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas
|
|
13 Dec 2011 |
Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)
|
|
12 Dec 2011 |
Micromet’s Blinatumomab Produces High Rate of Durable Hematologic Complete Remissions in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
|
|
12 Dec 2011 |
ABLYNX AND MERCK SERONO SELECT A NOVEL NANOBODY CANDIDATE, ALX-0761, FOR PRE-CLINICAL DEVELOPMENT
|
|
12 Dec 2011 |
Celldex Therapeutics Presents Novel Preclinical Data on CDX-1127 at the American Society of Hematology Meeting in San Diego
|
|
12 Dec 2011 |
Anti-cancer activity of BI-505 demonstrated in animal model
|
|
12 Dec 2011 |
Impressive ZEVALIN(R) Data Highlighted at 53rd Annual Meeting of the American Society of Hematology; Spectrum to Increase Clinical Efforts to Expand ZEVALIN Indications
|
|
11 Dec 2011 |
Genmab Announces Preliminary Safety and Efficacy Data for Daratumumab
|
|
11 Dec 2011 |
Micromet’s Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients
|
|
08 Dec 2011 |
Genentech Announces Positive Results of Pivotal Phase III Study with pertuzumab in HER2-Positive Metastatic Breast Cancer
|
|
07 Dec 2011 |
Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim
|
|
07 Dec 2011 |
Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
|
